GLP-1 and Gastric Retention: What to Know Before Surgery

GLP-1 therapy slows gastric emptying, creating important considerations for perioperative care and anesthesia.

The Gastric Emptying Effect

GLP-1 receptor agonists slow gastric emptying significantly, which is one of their primary weight loss mechanisms. However, this same effect creates a risk for patients undergoing procedures requiring fasting, as stomach contents may remain longer than expected. This has led to updated anesthesia guidelines recommending GLP-1 discontinuation before elective procedures.

The duration of discontinuation depends on the specific GLP-1 agent — short-acting formulations may require 24 hours, while weekly formulations may require 1-2 weeks.

Clinical Guidelines

Major anesthesia societies now recommend holding GLP-1 therapy before elective surgery. The American Society of Anesthesiologists suggests stopping weekly GLP-1 agonists one week before elective procedures and daily formulations on the day of surgery. Patients should inform their surgical team about GLP-1 use well in advance of any planned procedures.

Practical Considerations

For users planning elective procedures, coordinate with both the prescribing physician and surgical team. The timing of GLP-1 discontinuation should balance surgical safety against the risk of weight regain during the hold period. Emergency procedures require the anesthesia team to be aware of GLP-1 use for aspiration risk assessment.

Important Disclaimer

This article is for educational and research purposes only. Peptides discussed may not be FDA-approved for all uses described. Always consult with a qualified healthcare provider before starting any peptide protocol. The information provided here is synthesized from published research, clinical trial data, and community discussions.

Keywords: GLP-1, gastric retention, surgery, anesthesia, perioperative care

Sources: Published research papers, clinical trial databases, community discussions, peptiq.io educational content